Results 31 to 40 of about 8,788 (204)

Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents [PDF]

, 2022
BACKGROUND: The efficacy on the Omicron variant of the approved early- coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are ...
Alessandra, Vergori, Alessandro, Cozzi Lepri, Andrea, Antinori, AnnaRosa, Garbuglia, Claudia, Cimaglia, Eleonora, Lalle, Emanuela, Caraffa, Emanuele, Nicastri, Enrico, Girardi, Eugenia, Milozzi, Fabrizio, Carletti, Fabrizio, Maggi, Francesca, Colavita, Francesco, Vaia, Gaetano, Maffongelli, Ilaria, Mastrorosa, INMI COVID-19 Outpatient Treatment Study Group, Jessica, Paulicelli, Lavinia, Fabeni, Pierluca, Piselli, Raffaella, Libertone, Serena, Vita, Silvia, Rosati, Simone, Lanini, Valentina, Mazzotta   +24 more
core   +2 more sources

Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals [PDF]

, 2022
We report the use of combination therapy with remdesivir and nirmatrelvir/ritonavir (Paxlovid) in successfully treating severe, chronic COVID-19 caused by persistent SARS-CoV-2 infection over 4 months.
Snell, Luke Blagdon, Bakrania, Prijay, Williams, Tom G.S., Tam, Jerry, Da Silva Fontoura, Dayana, Shaw, Emily, Daunt, Anna, Edgeworth, Jonathan, Hemsley, Carolyn J., Fields, Paul, Agarwal, Sangita, Lams, Boris, Cahill, Helen, Milligan, Iain, Botgros, Alina, Nebbia, Gaia, Douthwaite, Sam, Aarons, Emma J.   +17 more
core  

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study [PDF]

, 2023
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause mortality in community-dwelling COVID-19 patients treated with these drugs ...
Erne, Elke Maria, Russo, Pierluigi, Tacconelli, Evelina, Tascini, Carlo, Torti, Carlo   +4 more
core   +1 more source

Tacrolimus Toxicity in Two Renal Transplant Recipients Treated With Nirmatrelvir/Ritonavir: A Case Series

Annals of Internal Medicine: Clinical Cases, 2023
Since the onset of the SARS-CoV-2 (COVID-19) pandemic, significant effort has been devoted toward developing therapeutics that decrease the morbidity and mortality of COVID-19 infection.
Meaghan Coyne, Myint Aye
doaj   +1 more source

Antivirals for the treatment of mild and moderate COVID-19 in South Africa [PDF]

, 2023
While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services.
Gengiah, T N, Govender, S, Naidoo, V, Perumal, R   +3 more
core   +2 more sources

The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao   +4 more
doaj   +1 more source

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. [PDF]

, 2023
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore,
Bardiot, Dorothée, Beigelman, Leonid, Blatt, Lawrence M, Boland, Sandro, Chaltin, Patrick, De Jonghe, Steven, De Vita, Chloe, Deval, Jerome, Donckers, Kim, Ebert, Nadine, Jekle, Andreas, Jochmans, Dirk, Liu, Cheng, Maes, Piet, Marchand, Arnaud, Neyts, Johan, Raboisson, Pierre, Stevens, Sarah K, Stoycheva, Antitsa, Symons, Julian A, Thiel, Volker, Trüeb, Bettina, Vandyck, Koen, Vangeel, Laura, Vanmechelen, Bert   +24 more
core   +2 more sources

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System

Infectious Diseases and Therapy
Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients nationally. Methods We conducted a retrospective cohort study among
Haley J. Appaneal, Kerry L. LaPlante, Vrishali V. Lopes, Catherine Martin, Laura Puzniak, Timothy L. Wiemken, Evan J. Zasowski, John M. McLaughlin, Aisling R. Caffrey   +8 more
doaj   +1 more source